REDX PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9 GBX | -10.00% |
|
-25.00% | -59.09% |
| Apr. 19 | Redx Pharma shareholders approve AIM delisting plans | AN |
| Apr. 19 | Redx Pharma Gets Shareholder Approval for Delisting from AIM | MT |
Presenter SpeechRachel Gravesen (Attendees)Hello, and welcome. Thanks for joining us for today...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovering and developing of novel, small molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Companyâs product pipeline includes RXC004, RXC007 (ROCK2 selective inhibitor) and RXC008. RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme Porcupine, a key activator of Wnt-ligands in the Wnt signaling pathway. Selective ROCK2 inhibitor for the treatment of interstitial lung diseases with an initial study in idiopathic pulmonary fibrosis. RXC007 is a potent, selective and orally active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), which sits at a nodal point in cell signaling pathways, central to fibrosis. RXC008 for the treatment of fibrostenotic Crohnâs disease.
Calendar
2024-06-09
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.09
GBP
Average target price
1.3
GBP
Spread / Average Target
+1,344.44%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -59.09% | 43.61M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- REDX Stock
- News Redx Pharma Plc
- Transcript : Redx Pharma Plc, H1 2023 Earnings Call, May 17, 2023
